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ABSTRACT. Background: ω-3 polyunsaturated fatty acids (PUFAs) and ω-6 PUFAs have 
opposing influences upon inflammation. Our objective was to determine whether 
lipopolysaccharide (LPS)-induced cytokine release by human alveolar cells was affected by 
changes of the ω-3/ω-6 ratio in cell membranes induced by different PUFA supplies. 
Methods: After LPS challenge, PUFAs were added to alveolar cells as docosahexaenoic acid (DHA, 
ω-3) plus arachidonic acid (AA, ω-6) in four different DHA/AA ratios (1:1, 1:2, 1:4, and 1:7) and 
cytokine release was measured. 
Results: The supply of 1:1 and 1:2 DHA/AA ratios reversed the baseline predominance of ω-6 over 
ω-3 in the ω-3/ω-6 PUFA ratio of cell membranes. The release of pro-inflammatory cytokines 
(TNF-α, IL-6, and IL-8) was reduced by 1:1 and 1:2 DHA/AA ratios (p < .01 to < .001), but 
increased by 1:4 and 1:7 DHA/AA ratios (p < .01 to < .001) vs. control. The 1:1 and 1:2 ratios 
increased the release of anti-inflammatory IL-10 (p < .001). The balance between pro- and anti-
inflammatory cytokines showed an anti-inflammatory response with 1:1 and 1:2 ratios and a pro-
inflammatory response with 1:4 and 1:7 ratios (p < .001). 
Conclusions: This study showed that pro-inflammatory cytokine release was dependent on the 
proportion of ω-3 in ω-3/ω-6 ratio in alveolar cell membranes, being reduced with the supply of 
high proportion of DHA and increased with high proportion of AA, respectively. Our results 
support the biochemical basis for current recommendations to shift the PUFA supply from ω-6 to 
ω-3 in nutrition of acute lung injury patients. 
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Acute lung injury (ALI) is characterized by an intense inflammatory response within the alveolar 
spaces,1 with accumulation of pro- and anti-inflammatory cytokines.2 Several studies have been 
carried out to find strategies for reducing the severity of lung inflammatory process, e.g. by 
reducing the release of pro-inflammatory mediators; however, few studies have demonstrated a 
significant effect on mortality in patients with acute respiratory distress syndrome (ARDS).3 
Treatment of patients with ALI/ARDS includes nutritional support with lipids; usually, soybean oil-
based lipid emulsions are used. These emulsions are rich in ω-6 polyunsaturated fatty acids 
(PUFAs) (i.e. linoleic acid) and poor in ω-3 PUFAs: thus, the ratio between ω-3 and ω-6 is quite 
low (between 1:5 and 1:7). An equally low ω-3/ω-6 PUFA ratio is typical of most enteral formulas. 
Consequently, ALI/ARDS patients are usually exposed to a relatively large amount of ω-6 PUFAs 
compared with ω-3,4 although administration of high amounts of linoleic acid appears to be 
undesirable in ARDS patients.5 
Several studies clearly demonstrated in lung cells that ω-6 PUFAs (e.g. arachidonic acid/AA) are 
precursors of pro-inflammatory mediators, as well as the pivotal role of AA and its metabolites as 
mediators of injury.6,7 Conversely, administration of ω-3 PUFAs (e.g. eicosapentaenoic acid/EPA 
and docosahexaenoic acid/DHA) has been demonstrated to decrease alveolar production of pro-
inflammatory mediators and to reduce organ failure in lung animal models.7-9 Based on these data, 
several reviews suggested that ω-3 PUFAs could modulate the pulmonary inflammatory 
response4,10 and represent a non-ventilatory therapeutic tool for ARDS.11 Three studies showed that 
enteral nutrition with EPA, gamma-linolenic acid, and antioxidants reduced alveolar inflammatory 
mediators and improved clinical outcomes in ALI/ARDS patients,12,13 as well as in ventilated severe 
septic patients.14 Parenteral nutrition (PN) with an ω-3 enriched lipid emulsion in ARDS patients 
showed selective anti-inflammatory effects.15 However, in contrast to ω-3 enteral administration,16 
to date no randomized controlled clinical trial using ω-3 enriched parenteral lipid emulsions has 
shown clear evidence of beneficial effects on clinical end-points in ALI/ARDS patients.17 
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Evidence is accumulating that the ω-3/ω-6 PUFA ratio in nutritional support may influence 
inflammation. Optimal ω-3 administration is not only dose-related but is also independently 
affected by the ω-3/ω-6 ratio.18 Though ω-3/ω-6 PUFA ratios from 1:1 to 1:4 have been 
proposed,4,19-25 the impact of ω-3/ω-6 ratio on the inflammatory response is still an unresolved 
question. Indeed, PN with the 1:2 ω-3/ω-6 PUFA ratio did not affect inflammation or clinical 
outcomes, compared to PN with a MCT/LCT emulsion in unselected critically ill medical patients.26 
No previous study has investigated the effects of supply of different ω-3/ω-6 ratios on 
phospholipid composition of cell membranes and cytokine release in the presence of a pro-
inflammatory stimulus in alveolar cells. The aim of our study was to determine whether changes of 
the ω-3/ω-6 PUFA ratio in cell membrane phospholipid composition induced by PUFA supply may 
have effects upon the release of pro-inflammatory cytokines (TNF-α, IL-6, and IL-8) and one anti-
inflammatory cytokine (IL-10) from human alveolar cells after endotoxin challenge. 
 
Materials and Methods 
Fatty acids (FAs) and LPS from Escherichia coli 055:B5 were obtained from Sigma Chemical Co. 
(St. Louis, MO). A human lung carcinoma cell line (A549 cells, ATCC, Rockville, MD) was used. 
A549 are alveolar epithelial cells with type II pneumocyte properties. The A549 cell cultures were 
treated as previously described.27 
Preliminary tests 
The study was preceded by the following preliminary tests performed in triplicate to design the 
experimental model. 
Test 1. Analysis of baseline A549 cell FA composition. The FA percentage content was determined 
in neutral and polar lipids as previously described.28 Briefly, total lipids were isolated by the Folch29 
method and separated by thin-layer chromatography. FA methyl esters from phospholipids were 
prepared following the Metcalfe30 method and separated by gas-liquid chromatography (CP 9002 
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Chrompack). Internal standard (methyl heptadecanoate) was added to each preparation to determine 
recovery. 
Test 2. Effects of PUFA addition (10, 25, and 50 µM) without LPS stimulation on the cytokine 
release and the phospholipid composition of A549 cells. 
Test 3. Effect of LPS challenge on A549 cells. Cells were exposed to various doses of LPS (100, 
200, and 400 µg/ml) to determine the dose- and time-dependence of LPS on cytokine release as 
assessed by TNF-α release. 
Experimental study 
Six different cultures of A549 cells were prepared: 1) baseline, non-stimulated cells; 2) control, 
cells stimulated with LPS at time 0; 3) DHA/AA1:1, cells stimulated with LPS and exposed to 
DHA(25 µM)/AA(25 µM) ratio; 4) DHA/AA1:2, cells stimulated with LPS and exposed to 
DHA(17 µM)/AA(33 µM) ratio; 5) DHA/AA1:4, cells stimulated with LPS and exposed to 
DHA(10 µM)/AA(40 µM) ratio; 6) DHA/AA1:7, cells stimulated with LPS and exposed to 
DHA(6.5 µM)/AA(43.5 µM) ratio. Three h after LPS challenge, DHA/AA ratios (50 µM) were 
added to cell cultures for 4 h. After 7 h from time 0, the release of TNF-α, IL-6, IL-8, and IL-10 in 
supernatant and the phospholipid composition of A549 cell membranes were determined (four 
independent experiments). All culture supernatants were harvested and stored at -80°C for cytokine 
measurement via ELISA kits (Euroclone, Paignton-Devon, UK) according to the manufacturer 
instructions). 
Statistical analysis 
Data were expressed as mean ± SD. Multiple comparisons were carried out using one-way 
ANOVA, followed by Bonferroni post hoc test. SPSS 14 (SPSS Inc., Chicago, IL) was used for 
analyses. Significance was defined as p < .05. 
 
Results 
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Preliminary tests 
Test 1. The FA percentage content in phospholipids of A549 cell membranes was shown in table 
1. 
Test 2. Both AA and DHA addition (50 µM) changed respective percentage content in 
phospholipids and ω-3/ω-6 PUFA ratio of A549 cells at 7 h (p < .001 vs. baseline) (Table 2). The 
TNF-α and IL-6 constitutive production was decreased by DHA (50 µM) (p < .05 and < .001, 
respectively) and increased by AA (50 µM) (p < .01 and < .001, respectively) at 7 h. Addition of 10 
µM PUFA did not induce significant modifies of the cytokine release and the phospholipid 
composition, whereas no difference between addition of 25 and 50 µM PUFA was found at 7 h. 
Test 3. A dose- and time-dependent effect of LPS on TNF-α release was observed. Concentration 
and exposure-time of LPS that induced the most significant TNF-α release were 400 µg/ml and 7 h, 
respectively (p < .001). 
As previously demonstrated, A549 cell growth was decreased in a concentration- and time-
dependent manner by addition of AA27 and DHA;28 however, at 7 h no difference on A549 cell 
proliferation and viability versus baseline was found after 50 µM AA or DHA addition, as well after 
LPS challenge. Based on the results of these preliminary tests, we designed for the experimental 
study the LPS challenge of 400 µg/ml for 7 h and the addition of DHA/AA ratios in a total final 
concentration of 50 µM. 
Experimental study 
Effect of LPS and DHA/AA ratios on phospholipid composition of A549 cell membranes (Table 1) 
In control cells, we observed a remarkable decrease of AA percentage content (p < .001 vs. 
baseline), while DHA did not change in phospholipids of cell membranes. Following addition of 
different DHA/AA ratios, the DHA (p < .001 vs. all) and AA (p < .05 to < .001 vs. all, except 1:4 
vs. 1:7) contents were changed. Finally, the ω-3/ω-6 PUFA ratio in cells exposed to 1:1 and 1:2 
DHA/AA ratios was markedly changed (p < .001 vs. all). 
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Effect of DHA/AA ratios on LPS-induced cytokine release from A549 cells (Fig. 1 A-B-C-D) 
The release of TNF-α, IL-6, IL-8, and IL-10 from control was considerably increased (p < .001) 
compared with baseline. The 1:1 DHA/AA ratio decreased TNF-α, IL-6, and IL-8 release (p < .001) 
compared with control, as well as, the 1:2 DHA/AA ratio decreased TNF-α (p < .001), IL-6 (p < 
.01), and IL-8 (p < .01), but less than the 1:1 ratio (p < .001). Exposure of cell cultures to 1:4 
DHA/AA and 1:7 DHA/AA ratios increased the release of TNF-α (p < .01), IL-6 (p < .001), and IL-
8 (p < .001) vs. control. Such increase in release of pro-inflammatory cytokines was also significant 
vs. 1:1 and 1:2 ratios (p < .001). The release of IL-10 was increased by 1:1 and 1:2 ratios (p < .001), 
while it was not affected by 1:4 and 1:7 ratios. 
Effect of DHA/AA ratios on balance between pro- and anti-inflammatory cytokines (Fig. 2 A-B-C) 
The balance between pro- and anti-inflammatory cytokines was evaluated by three cytokine ratios 
(TNF-α/IL-10, IL-6/IL-10, and IL-8/IL-10): a reduction of such ratios was considered as an anti-
inflammatory response, while an increased ratio was considered a further amplification of the pro-
inflammatory response. The three cytokine ratios showed the same pattern. An anti-inflammatory 
response was observed with 1:1 and 1:2 ratios (p < .001), due to the net effect of a reduction of 
TNF-α, IL-6, and IL-8 plus an increase of IL-10 concentrations. On the contrary, a pro-
inflammatory response was observed when 1:4 and 1:7 ratios (p < .001). 
 
Discussion 
The main finding of this study was that the supply of 1:1 and 1:2 DHA/AA ratios reversed the 
baseline predominance of ω-6 over ω-3 in the ω-3/ω-6 PUFA ratio of cell membranes, decreasing 
the release of TNF-α, IL-6, and IL-8 in alveolar cells. In contrast, the supply of DHA/AA ratios 
with an ω-6 prevalence (i.e. 1:4 and 1:7) caused itself a further significant increase in pro-
inflammatory cytokine release compared with LPS alone. Thus, the balance between the release of 
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pro- and anti-inflammatory cytokines showed a relevant anti-inflammatory response with 1:1 and 
1:2 ratios and a pro-inflammatory response with 1:4 and 1:7 ratios. 
The reason some patients with ALI develop ARDS whereas others recover remains unclear. 
Inflammatory cytokines are key elements in the pathogenesis of ARDS and they appear to have 
concentration-dependent biologic effects. Persistently alveolar elevated levels of pro-inflammatory 
cytokines associated with decreased production of those anti-inflammatory correlate with the 
severity of lung injury, and the degree of this cytokine imbalance leads to additional non-pulmonary 
organ dysfunction and increased mortality rates in ARDS patients.2,31,32 Previous studies suggested 
that the lung itself can be an important cytokine-producing organ and the type II pneumocytes have 
a central position in the pathophysiology of the alveolar space.33 
Lipids are known to have immune-modulatory properties and their administration could influence 
the prognosis of ALI/ARDS patients.17 Indeed, after PUFA challenge many cell properties are 
shown to be modified, mainly the inflammatory response (e.g. eicosanoid and cytokine 
productions).23,25,34,35 In general, ω-3 PUFAs are regarded to be anti-inflammatory whereas ω-6 are 
pro-inflammatory.34 The differential impact of ω-3 vs. ω-6 supply on cytokine generation provoked 
by various stimuli was demonstrated in respiratory cells,35 as well as in septic and ALI murine 
models.36,37 In septic patients, ω-3 PUFA parenteral administration influenced lipid mediator 
generation and reduced endotoxin-elicited monocyte pro-inflammatory cytokine generation, while 
cytokine generation was markedly amplified by ω-6 PUFA infusion.38 The alveolar cells have an 
intense lipid metabolism and, as demonstrated both in A549 cells and lung models, EPA/DHA are 
rapidly incorporated in the phospholipids of lung cell membranes, inducing rapidly (from 5 min to 4 
h) changes in cell membrane FA composition9 and lipid-derived inflammatory mediator 
generation.8,9,39 
A complex network of factors regulates the relation between ω-3 and inflammation25,34,40 and the 
mechanisms underlining the anti-inflammatory effects of DHA are not completely clear; however, 
DHA seems to be more effective than EPA in alleviating LPS-induced pro-inflammatory cytokine 
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production in macrophages.41 One of the goal of EPA/DHA supplementation is to reduce the 
severity of inflammatory processes by reducing the availability of AA in cell membranes.10 
Moreover, DHA can decrease the release of AA from membrane phospholipids by decreasing 
phospholipase A2 activity.42 A decrease in AA leads to reduced release of pro-inflammatory 
mediators (prostaglandin E2 and leukotriene B4).34 Our findings indicate that the baseline 
predominance of ω-6 over ω-3 was reversed following the supply of 1:1 and 1:2 ratios, with the 
DHA exceeding the AA content nearly 4-8-fold. Thus, a remarkable change in the ω-3/ω-6 PUFA 
ratio in membranes of alveolar cells occurred, with the ratio raised from 1:5 to 6:1 and 3:1, 
respectively. According to numerous available data, we believe that a manipulation of PUFA supply 
modifies the cell membrane structure and consequently its function.9,10,20,38,43 Indeed, there is a 
close association between the change of membrane-associated protein function linked to ω-3 supply 
and the LPS-stimulated cytokine response44 (e.g. DHA decreases the responsiveness of TLR-4 to 
LPS).42 The ω-3 fatty acid decreases the production of cytokines (TNF-α, IL-1β, IL-6, and IL-8) 
acting both directly, by replacing AA in cell membranes, and indirectly by decreasing activation of 
pro-inflammatory transcription factors (e.g. NFκ-B) and increasing activation of anti-inflammatory 
transcription factors (e.g. peroxisome proliferator activated receptor γ).34 
An increased IL-10 (a potent anti-inflammatory cytokine) concentration was detected in 
supernatant of alveolar cells treated with 1:1 and 1:2 ratios. Moreover, in alveolar cells treated with 
the 1:1 ratio we found that the TNF-α/IL-10 ratio was 0.79, which is similar to that (i.e. 0.85) found 
in the bronchoalveolar lavage of patients who did not develop ARDS.45 It was demonstrated that IL-
10 suppresses LPS-induced production of TNF-α, IL-1β, and IL-6 in vitro, as well as reduces TNF-
α  concentrations post-LPS challenge in animals.46 Thus, we hypothesized that the increased release 
of IL-10 could be another factor contributing to the reduction of pro-inflammatory cytokine release 
observed in our study. 
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In the alveolar spaces the balance between pro- and anti-inflammatory responses is a critical 
element for progression of ALI, and early activation of an anti-inflammatory response through an 
ω-3 supplementation could provide a mechanism for limiting the inflammatory response. However, 
the ω-3 supplementation is not completely without risk due to a potential excessive reduction in 
pro-inflammatory response, which could induce immunosuppression.21 The ω-3/ω-6 ratio of 1:2.1 
was considered ‘neutral’ in terms of ‘immunosuppressive’ effects.19 In our study, both 1:1 and 1:2 
ratios shifted the balance between pro- and anti-inflammatory cytokines towards an anti-
inflammatory response; however, we believe that the 1:2 ω-3/ω-6 ratio should be preferred because 
it could combine efficacy and low risk of ‘immunosuppressive’ effects. 
The novelties of this study are the use of different PUFA ratios and the use of the alveolar cell 
line; the limit is that we do not investigate what transcriptional mechanisms are at work in our 
experimental model. In fact, the study was designed as an explorative investigation and further 
studies are necessary to offer more mechanistic insights. 
In conclusion, this study has shown that shifting the PUFA supply from AA to DHA reduced 
significantly the release of pro-inflammatory cytokines in human alveolar cells undergoing 
inflammatory stress. Unexpectedly, we found that in the presence of a PUFA ratio with an AA 
predominance there was a cytokine balance more oriented to a pro-inflammatory response than with 
LPS alone. Our results suggest that the change of the ω-3/ω-6 ratio in PUFA supply could be an 
important factor affecting the alveolar cytokine release. Finally, these data support the biochemical 
basis for current recommendations47,48 to shift the lipid supply from ω-6 to ω-3 PUFA in nutritional 
support of ALI/ARDS patients. 
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Figure legends 
Figure 1 
Effect of ω-3/ω-6 PUFA ratios on LPS-induced cytokine release from A549 cells. The results are 
expressed as picograms of released cytokines per 106 adherent cells (pg/106 cells). Data are 
presented as median with interquartile ranges (n = 4 experiments). (A) TNF-α: *p < .001 vs. all; §p 
< .01 vs. control. (B) IL-6: *p < .001 vs. all; **p < .01 vs. control; §p < .001 vs. control and 1:2. (C) 
IL-8: *p < .001 vs. all; **p < .01 vs. control; §p < .001 vs. control and 1:2. (D) IL-10: *p < .001 vs. 
all. 
 
Figure 2 
Effect of ω-3/ω-6 PUFA ratios on balance between pro- and anti-inflammatory cytokines. The 
balance was evaluated by three cytokine ratios (TNF-α/IL-10, IL-6/IL-10, and IL-8/IL-10). The 
results are expressed as log10 picograms of released cytokines per 106 adherent cells (log10 pg/106 
cells). Data are presented as median with interquartile ranges (n = 4 experiments). *p < .001 vs. all; 
§p < .001 vs. control. 
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Table 1. Percentage content of fatty acids in phospholipids of A549 cell membranes at 7 h 
 
 
Fatty acid 
Baseline Control DHA/AA
1:1 
DHA/AA
1:2 
DHA/AA
1:4 
DHA/AA
1:7 
 
C14:0 3.7 7.2 7 6.9 7.4 7.5 
C16:0 31.9 56.5 51.2 52 58.2 59.7 
C16:1 9.6 1.8 1.6 1.9 2 2.2 
C18:0 16.8 26.6 17.2 18.1 15.2 14.2 
C18:1 27.3 4.3 3.5 3.9 4.8 5 
C18:2 2.8 0.5 0.6 0.8 1.6 1.8 
C20:4 (AA) 6.2§ 0.9§ 2.2§ 3.5§ 4.5§ 4.9§ 
C22:6 (DHA) 1.7 2.2 16.7* 12.9* 6.3* 4.7* 
ω-3/ω-6 PUFA ratio 1:5 1.6:1 6:1* 3:1* 1:1 1:1.4 
PUFA, Polyunsaturated Fatty Acid; AA, arachidonic acid; DHA, docosahexaenoic acid. 
Data are expressed as percentage of fatty acids and are means of 4 experiments. SD (not 
shown) was below 10% in all cases. Percentage content of fatty acids less than 0.5% were 
not reported. §p < .05 to < .001 vs. all, except 1:4 vs. 1:7. *p < .001 vs. all. 
Table 2. Percentage content of fatty acids in phospholipids of A549 cell membranes at 7 h 
 
 
Fatty acid 
  Baseline AA 
(50 µM) 
DHA 
(50 µM) 
C20:4 (AA) 6.1 13.5* 3.5§ 
C22:6 (DHA) 1.8 1.3 9.6* 
ω-3/ω-6 PUFA ratio 1:5 1:12* 2:1* 
PUFA, Polyunsaturated Fatty Acid; AA, arachidonic acid; DHA, docosahexaenoic acid. 
Data are expressed as percentage of fatty acids and are means of 3 experiments. SD (not 
shown) was below 10% in all cases. §p < .05 vs. baseline, *p < .001 vs. baseline. 
